Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$322.02M, compared with -$461.47M a year earlier.
Context
- Net debt amounted to 58.2% of total assets at the end of Q1 FY2026, down 38.4 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +30.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (94.98M) USD
- Year-over-year change
- +80.6%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (94.98M) | +80.6% |
| FY2024 | 2024-12-31 | (488.97M) | -112.8% |
| FY2023 | 2023-12-31 | (229.78M) | -5426.3% |
| FY2022 | 2022-12-31 | (4.16M) | — |
Net Debt vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 net debt of -$322.02M is the lowest of the 6 companies compared; the peer median is -$54.25M.
- Its year-over-year change of +30.2% is the 3rd highest of 6, against a peer median of +2.8%.
- Net debt amounts to 58.2% of total assets for BCAX, versus a peer median of 22.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$30.01M | +72.2% | — | 13.8% | |
| Mar 2026 | -$45.38M | -30.9% | — | 22.1% | |
| Mar 2026 | -$54.25M | +39.2% | — | 92.2% | |
| Mar 2026 | -$72.7M | +2.8% | — | 18.0% | |
| Mar 2026 | -$187.62M | -3241.9% | — | 94.2% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | -$322.02M | +30.2% | — | 58.2% |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | -$54.25M | +2.8% | — | 22.1% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.